FDA Approves Insulet SmartAdjust Device for Type 2 Diabetes Management

FDA Approval of Insulet SmartAdjust Device

On August 27, 2024, the FDA approved the Insulet SmartAdjust device for automatic insulin dosing in individuals with type 2 diabetes, marking a significant expansion from its previous use exclusively for type 1 diabetes.

The Insulet SmartAdjust device integrates with both an insulin pump and a continuous glucose monitor to automatically adjust insulin delivery. This advancement allows patients to achieve better glycemic control with less manual intervention, thereby enhancing their quality of life and enabling them to focus more on other aspects of their daily activities.

In a study involving 289 participants with type 2 diabetes, the device demonstrated notable improvements in blood sugar management. Participants maintained blood glucose levels within target ranges more consistently. Importantly, the study reported no serious complications, underscoring the device's safety and efficacy for managing type 2 diabetes.

Regulatory Impact

Top Priority: Yes
Type of Certificate: No
Spectrum Bands: No
Import Changes HS Codes: No
Standard Changes: No
Products Changes: Yes
Label Changes: No

Link to Source - https://www.fda.gov/news-events/press-announcements/la-fda-autoriza-el-primer-dispositivo-que-permite-la-dosificacion-automatica-de-insulina-para

Impact Type	Status
Top Priority
Type Certificate
Spectrum Bands
Import Changes (HS Codes)
Standard Changes
Product Changes
Label Changes